Literature DB >> 8464301

Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents.

V G Schweitzer1.   

Abstract

Cis-diamminedichloroplatinum II (cisplatin), a divalent platinum compound and potent cell-cycle nonspecific chemotherapeutic agent, produces a dose-limiting, permanent, high-frequency sensori-neural hearing loss and peripheral neuropathy, and a dose-related cumulative renal insufficiency with tubular necrosis and interstitial nephritis. The potential for dose-limiting and permanent cochlear (neuro) toxicity remains despite present methods of hypertonic saline, prehydration, and mannitol diuresis prior to drug administration. The exact mechanism(s) of ototoxicity and/or nephrotoxicity are still unknown. Continued aggressive high-dose cisplatin chemotherapy necessitates the investigation of ways to decrease the dose-limiting side effects that inhibit the administration of cisplatin at therapeutic and tumoricidal doses. This multifaceted project investigates two categories of potential inhibitors of cisplatin toxicity that, when coadministered with a known tumoricidal and ototoxic dose of cisplatin, will decrease or inhibit the ototoxicity: 1. phosphonic acid antibiotics (fosfomycin; 1,2 epoxypropylphosphonic acid); 2. nonglucocorticoid 21-aminosteroids, which are free oxygen radical scavengers (LAZAROIDS: U74006F and U78517F). This project also investigates the role of pigmentation as a variable affecting the evaluation of platinum-induced ototoxicity in the guinea pig animal model. Identification of an optimal animal model for future cisplatin toxicity research should be based on previously established species-specific differences in total drug dose, systemic toxicity, and morphological and functional evidence of cochlear toxicity, as affected by differences in pigmentation and drug tolerance. Cytocochleography, brainstem auditory evoked response (BSER), scanning and transmission electron microscopy of organ of Corti and the stria vascularis, double-blind light microscopy of renal, small intestine, and peripheral nerve tissue, and gamma-emission analysis of 195Mplatinum localization in inner ear neuroepithelium and the stria vascularis are used in the global evaluation of the ototoxic effects of cisplatin in both the adult albino and pigmented guinea pig.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464301

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  25 in total

1.  Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.

Authors:  Angela C Garinis; Douglas H Keefe; Lisa L Hunter; Denis F Fitzpatrick; Daniel B Putterman; Garnett P McMillan; Jeffrey A Gold; M Patrick Feeney
Journal:  Ear Hear       Date:  2018 Jan/Feb       Impact factor: 3.570

2.  Is intratympanic injection of erdosteine protective against cisplatin-induced ototoxicity?

Authors:  Issam Saliba; Fouad El Fata
Journal:  Neurotox Res       Date:  2011-10-12       Impact factor: 3.911

3.  Ameliorative effect of flunarizine in cisplatin-induced acute renal failure via mitochondrial permeability transition pore inactivation in rats.

Authors:  Arunachalam Muthuraman; Shailja Sood; Sumeet Kumar Singla; Ajay Rana; Atinderjeet Singh; Amandeep Singh; Jai Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-31       Impact factor: 3.000

4.  Development and validation of a cisplatin dose-ototoxicity model.

Authors:  Marilyn F Dille; Debra Wilmington; Garnett P McMillan; Wendy Helt; Stephen A Fausti; Dawn Konrad-Martin
Journal:  J Am Acad Audiol       Date:  2012 Jul-Aug       Impact factor: 1.664

5.  Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.

Authors:  Dawn Konrad-Martin; Kenneth E James; Jane S Gordon; Kelly M Reavis; David S Phillips; Gene W Bratt; Stephen A Fausti
Journal:  J Am Acad Audiol       Date:  2010-05       Impact factor: 1.664

6.  Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).

Authors:  Dawn Konrad-Martin; Kelly M Reavis; Garnett McMillan; Wendy J Helt; Marilyn Dille
Journal:  J Rehabil Res Dev       Date:  2014

7.  Effect of cisplatin on the negative charge barrier in strial vessels of the guinea pig. A transmission electron microscopic study using polyethyleneimine molecules.

Authors:  M Suzuki; K Kaga
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

8.  Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?

Authors:  Fang-Zhen Shen; Jing Wang; Jun Liang; Kun Mu; Ji-Yuan Hou; Yan-Tao Wang
Journal:  Int J Exp Pathol       Date:  2010-02       Impact factor: 1.925

Review 9.  Experimental, clinical and preventive aspects of ototoxicity.

Authors:  A A Chiodo; P W Alberti
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

10.  WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.

Authors:  Michael W Church; Brian W Blakley; Don L Burgio; Anil K Gupta
Journal:  J Assoc Res Otolaryngol       Date:  2004-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.